Neutrophil to Lymphocyte Ratio (NLR) is a Better Tool Rather than Monocyte to High-Density Lipoprotein Ratio (MHR) and Platelet to Lymphocyte Ratio (PLR) in Central Retinal Artery Occlusions

• Published in: Ocular immunology and inflammation Vol. 29; no. 5; pp. 997 - 1001
• Main Authors: Guven, Soner, Kilic, Deniz
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.07.2021
• Subjects: Aged; Aged, 80 and over; Biomarkers - blood; Blood Platelets - pathology; Central retinal artery occlusion; CRAO; Female; Humans; Lipoproteins, HDL - blood; Lymphocyte Count; Lymphocytes - pathology; Male; Middle Aged; monocyte to high-density lipoprotein ratio; Monocytes - pathology; neutrophil to lymphocyte ratio; Neutrophils - pathology; Platelet Count; platelet to lymphocyte ratio; Retinal Artery Occlusion - blood; Retinal Artery Occlusion - diagnosis; Retrospective Studies; ROC Curve; platelet to lymphocyte ratio; CRAO; neutrophil to lymphocyte ratio; Central retinal artery occlusion; monocyte to high-density lipoprotein ratio
• ISSN: 0927-3948; 1744-5078; 1744-5078
• DOI: 10.1080/09273948.2020.1712433

Purpose: To evaluate the predictive value of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to high-density lipoprotein (HDL) ratio (MHR) and blood lipid profile in central retinal artery occlusion (CRAO) patients. Methods: We included 37 patients with a diagnosis of CRAO and 36 healthy subjects with similar age-sex in the study. We analyzed the medical records of peripheral blood samples retrospectively. NLR, PLR, MHR were obtained by simple manually calculations. Results: CRAO patients had significantly higher mean NLR in comparison with healthy subjects (p: 0.009). The groups were similar in regard to mean PLR (p: 0.864) and mean MHR (p: 0.581). A cutoff value of >1.62 for NLR was found to be a diagnostic tool in CRAO. The sensitivity and specificity for this cutoff point was 83.8% and 55.6%, respectively. Conclusion: NLR rather than MHR and PLR may be a beneficial marker for the development of CRAO.